What's New in Systemic Lupus Erythematosus? Unlocking Novel Paths to Patient CareA LIVE Virtual Symposium During ACR Convergence 2020
This is not an official program of the American College of Rheumatology (ACR). However, you must be registered for ACR Convergence 2020 to attend this program.
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
This activity is supported by an independent educational grant from AstraZeneca.
The educational design of this activity addresses the needs of rheumatologists and other specialists involved in the management of patients with systemic lupus erythematosus (SLE).
Despite improved understanding of pathophysiologic mechanisms, additional assessment strategies, and hope for more available treatments, specialists face challenges in managing the diverse manifestations of, and patient populations with, SLE. During this live Engaging the Patient™ symposium, a panel of 3 experts in SLE will share interpretive insights on SLE pathophysiology, diagnosis, the use of classification criteria and measures of disease activity, and recent clinical trial data for newer targeted therapies. This forward-looking CME program aims to capture expert interpretations of existing and evolving evidence to help rheumatologists provide care that minimizes recurrent disease activity flares and cumulative organ damage that are key factors in long-term outcomes.
Upon completion of this activity, the participant should be better able to:
- Describe SLE pathophysiology with a focus on novel treatment targets
- Evaluate patients with SLE using evidence-based classification criteria and measures of disease activity
- Discuss new clinical trial data and regulatory status for current and emerging targeted therapies in moderate-to-severe SLE
- Manage patients with moderate-to-severe SLE based on a treat-to-target approach, evolving clinical evidence, unresolved symptoms, and patient preferences
6:00 pm – 6:10 pm Introduction and Preactivity Polling
6:10 pm – 6:30 pm How Do We Evaluate Patients with Suspected SLE?
6:30 pm – 6:50 pm Comprehensive Treatment of SLE: Where are We Now?
6:50 pm – 7:05 pm Insights into SLE Pathophysiology
7:05 pm – 7:20 pm Linking Pathophysiology to Targets for Drug Development
7:20 pm – 7:40 pm Patient Goals, Treat-to-Target, and Treatment Success
7:40 pm – 7:45 pm Faculty Closing Comments
7:45 pm – 8:00 pm Postactivity Polling and Ask the Experts Q&A Session
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Physician Continuing Medical Education
PIM designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
CPE Questions – PIM Contact Information
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at email@example.com.